Baird Medical Accelerates U.S. Expansion at NASOIE 2026

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) highlighted its U.S. expansion strategy by participating at the NASOIE 2026 Annual Meeting in Miami on March 2, 2026.

The company engaged clinicians on its proprietary microwave ablation (MWA) technology, gathered clinical feedback, and said that insights will inform its commercial roadmap to expand patient access to minimally invasive therapies.

Key Figures

Share price: $3.03 Daily move: 30.7% Trading volume: 5,320,343 shares +5 more

8 metrics

Share price $3.03 Post-news current price

Daily move 30.7% 24h price change on news date

Trading volume 5,320,343 shares Volume today vs 20-day average 4,618,167

Market cap $83,735,050 Equity value before considering warrant or resale overhang

Warrant shares 11,500,000 shares Ordinary shares issuable upon exercise of public warrants

Warrant exercise price US$11.50 Exercise price for public warrants

Registered resale shares 34,415,562 shares Ordinary shares registered for resale by existing holders

Resale share percentage 70.9% Portion of outstanding shares represented by registered resale shares

Market Reality Check

Price: $3.03 Vol: Volume 5,320,343 is 15% a...

normal vol

$3.03 Last Close

Volume Volume 5,320,343 is 15% above the 20-day average of 4,618,167. normal

Technical Trading at $3.03, which is above the 200-day MA of $2.36 and 58.27% below the 52-week high.

Peers on Argus

BDMD gained 30.7% while key peers were mixed: ICAD up 3.48%, XTNT up 3.69%, APYX...

2 Up

BDMD gained 30.7% while key peers were mixed: ICAD up 3.48%, XTNT up 3.69%, APYX down 4.66%, ICCM down 5.28%, NSPR down 1.66%. Momentum scanner flagged ICCM and NSPR both moving up 6–8%, but overall action does not clearly track BDMD’s magnitude.

Common Catalyst Multiple medical device peers also reported news-driven developments, including clinical study data and strategic transactions.

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	U.S. expansion update	Positive	+29.0%	Highlighted expanded U.S. clinical progress and adoption for benign thyroid conditions.
Feb 19	Conference showcases	Positive	+12.3%	Announced plans to showcase MWA thyroid solutions at three U.S. conferences.
Feb 11	Hospital launch	Positive	-7.6%	Commercial launch at Bakersfield Memorial Hospital with first benign thyroid ablation.
Feb 09	Global education programs	Positive	+9.7%	Clinical education initiatives in the U.S. and Japan to standardize techniques.
Jan 28	MWA masterclass	Positive	+6.9%	Gynecology microwave ablation masterclass to train physicians across Asia.

Pattern Detected

Recent news on U.S. expansion, clinical education, and hospital launches has usually led to positive one-day reactions, with one notable selloff after a commercial launch headline.

Recent Company History

Over the past months, Baird Medical has repeatedly highlighted its U.S. and global rollout of minimally invasive microwave ablation. Events on Jan 28, Feb 9, Feb 11, Feb 19, and Feb 25, 2026 focused on masterclasses, clinical education in the U.S. and Japan, hospital launches, and conference showcases. Most of these drew positive 24-hour moves, framing today’s NASOIE-focused expansion update as part of a continuing commercialization and physician-education push.

Market Pulse Summary

This announcement underscores continued investment in physician education and U.S. expansion for Bai...

Analysis

This announcement underscores continued investment in physician education and U.S. expansion for Baird Medical’s microwave ablation platform, now featured at the 2026 NASOIE meeting. It fits a series of recent commercialization and training milestones across the U.S. and Asia. Investors may track how clinician engagement at NASOIE translates into broader clinical adoption, while also weighing the implications of the 424B3 registering up to 45,915,562 shares for issuance and resale.

Key Terms

microwave ablation (mwa), interventional endocrinology

2 terms

microwave ablation (mwa) medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology"

Microwave ablation (MWA) is a minimally invasive medical procedure that uses focused microwave energy to heat and destroy unwanted tissue, such as tumors or lesions, without open surgery. Think of it like using a tiny, precise microwave oven inside the body to remove a problem area; for investors, MWA matters because its effectiveness, safety, costs, and adoption influence demand for related devices, hospital procedures, reimbursement and potential market growth.

interventional endocrinology medical

"NASOIE convenes top-tier clinicians to exchange advanced methodology in interventional endocrinology."

Interventional endocrinology is a medical subspecialty that treats hormone-producing glands and related conditions using minimally invasive procedures—such as targeted injections, ablations or catheter-based techniques—rather than open surgery or only drugs. For investors, it matters because these procedures create demand for specialized devices, outpatient services and new reimbursement pathways, so advances or approvals can shift revenue prospects much like a new tool changing how plumbers fix a pipe without tearing down the wall.

AI-generated analysis. Not financial advice.

NEW YORK, March 2, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation at the 2026 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Miami, Florida. Building on successful engagements at previous NASOIE gatherings, this initiative reinforces the Company's enduring commitment to physician education and advances its strategy to expand patient access to minimally invasive therapies.

NASOIE convenes top-tier clinicians to exchange advanced methodology in interventional endocrinology. At the event, Baird Medical engaged in discussions with attending physicians regarding the clinical applications and efficacy of its proprietary MWA technology. Through these interactions, the Company provided specialists with practical insights into integrating these advanced tools into their practice to achieve superior patient outcomes.

The clinical feedback gathered in Miami will directly inform Baird Medical's commercial roadmap. The Company remains focused on delivering innovative medical devices that address a broad spectrum of clinical applications with unmatched precision.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-us-expansion-at-nasoie-2026-302700652.html

SOURCE BDMD

FAQ

Why did Baird Medical (BDMD) attend NASOIE 2026 in Miami on March 2, 2026?

To engage clinicians and advance physician education on MWA technology. According to the company, the goal was to discuss clinical applications, share methodology, and reinforce its strategy to expand patient access to minimally invasive therapies.

What clinical topics did Baird Medical (BDMD) discuss at NASOIE 2026?

Clinical applications and efficacy of its proprietary microwave ablation technology. According to the company, discussions focused on practical integration into practice and techniques aimed at improving patient outcomes and procedural precision.

How will the clinical feedback from NASOIE 2026 affect Baird Medical's (BDMD) plans?

The feedback will shape the company’s commercial roadmap and product strategy. According to the company, insights gathered in Miami will directly inform go-to-market priorities and physician education efforts to increase patient access.

Does Baird Medical (BDMD) claim its MWA technology is suitable for broad clinical applications?

Yes, the company presented MWA as addressing a broad spectrum of clinical applications. According to the company, its devices are positioned to deliver precision and to be integrated into varied interventional endocrinology workflows.

Will Baird Medical (BDMD) continue engaging at future NASOIE meetings?

The company indicated ongoing participation based on prior successful engagements. According to the company, continued NASOIE involvement supports physician education and the firm’s U.S. expansion strategy for minimally invasive therapies.

How can investors interpret Baird Medical's (BDMD) NASOIE 2026 participation for growth prospects?

Participation signals focus on physician adoption and commercial expansion in the U.S. According to the company, clinician engagement and clinical feedback are intended to guide commercialization and patient-access initiatives for its MWA platform.